Foscarnet Sodium Chloride Injection

1. This product is a broad-spectrum antiviral drug, and its mechanism of action is to directly inhibit virus-specific DNA polymerase and reverse transcriptase. 2. This product has an inhibitory effect on herpes simplex virus type Ⅰ, type Ⅱ, cytomegalovirus, etc.

The main ingredient of this product is sodium foscarnet. The auxiliary materials are sodium chloride, sodium pyrosulfite and sodium calcium edetate.

1. Cytomegalovirus retinitis in patients with AIDS. 2. Acyclovir-resistant herpes simplex toxic mucocutaneous infections in patients with impaired immune function.

Intravenous drip. Individualized dosage. 1. Cytomegalovirus retinitis in patients with AIDS (normal renal function). Induction therapy: The initial dosage is 60 mg/kg, once every 8 hours, and the intravenous drip time should not be less than 1 hour. It should be used for 2 to 3 weeks according to the efficacy. Maintenance therapy: The maintenance dose is 90 to 120 mg/kg/day (the dose is adjusted according to renal function), and the intravenous drip time should not be less than 2 hours. During maintenance therapy, if the condition worsens, the induction therapy and maintenance therapy process can be repeated. 2. Acyclovir-resistant herpes simplex virus mucocutaneous infection in patients with impaired immune function. The recommended dose is 40 mg/kg, once every 8 or 12 hours, and the intravenous drip time should not be less than 1 hour. It should be used for 2 to 3 weeks or until cured. During the use of this product, renal function should be closely monitored and the dosage should be adjusted. See the table below for details: When using the above table, the actual measured value of 24-hour creatinine clearance (ml/min) should be divided by body weight, or the creatinine clearance (ml/min/kg) should be calculated according to the following formula

According to literature reports, the adverse reactions related to, unrelated to, and indeterminate from this product in prospective clinical trials of 188 AIDS patients and after the product was marketed are as follows: 1. Renal impairment: increased serum creatinine, decreased creatinine clearance, abnormal renal function, acute renal failure, uremia, polyuria, and metabolic acidosis. Serum creatinine values can return to pre-treatment levels or normal within 1-10 weeks after stopping medication. 2. Electrolyte: hypocalcemia, hypomagnesemia, hypokalemia, hypophosphatemia, or hyperphosphatemia. This product can chelate divalent metal ions (Ca2, Mg2, Fe2, Zn2). 30% of AIDS patients experience reversible hypocalcemia when using this product, which is dose-dependent. 3. Convulsions (including grand mal epileptic seizures): Although many patients may experience convulsions due to hypocalcemia or pre-existing diseases (cryptococcal meningitis, space-occupying lesions, or other central nervous system tumors), the relationship with this product cannot be ruled out. 4. Anemia or decreased hemoglobin: generally not accompanied by decreased white blood cell and platelet counts. Many AIDS patients receive AZT treatment at the same time and have anemia before receiving this product. 5. Local irritation: phlebitis at the injection site, irritation symptoms or ulcers in the reproductive and urinary tract. 6. Systemic: fatigue, malaise, chills, fever, sepsis. 7. Gastrointestinal system: nausea, vomiting, diarrhea, abdominal pain, indigestion, constipation, and individual cases of pancreatitis have been reported. 8. Metabolic and nutritional disorders: hyponatremia and lower limb edema, elevated lactate dehydrogenase, alkaline phosphatase or amylase. 9. Central and peripheral nervous systems: paraethesia, headache, dizziness, involuntary muscle contraction, tremor, ataxia, neuropathy. 10. Mental disorders: anorexia, anxiety, nervousness, mental confusion, depression, psychosis, agitation, aggressive reactions. 11. Hepatobiliary system: abnormal ALT and AST. 12. Cardiovascular: ECG abnormalities, hypertension or hypotension, ventricular arrhythmia. 13. Others: leukopenia, granulocytopenia, thrombocytopenia, rash, muscle weakness.

Contraindicated in case of hypersensitivity to sodium foscarnet.

Precautions for children: There is no experience of using this product for children. Precautions for pregnancy and lactation: Pregnant women should not use this product unless necessary. Lactating women should stop breastfeeding while using this product. Precautions for the elderly: No such test has been conducted and there is no reliable reference literature.

1. This product cannot be mixed with other drugs for intravenous drip. This product can only be diluted with 5% glucose or normal saline. 2. This product cannot be used simultaneously with other nephrotoxic drugs such as aminoglycoside antibiotics, amphotericin B or vancomycin. 3. This product cannot be used in combination with intravenous pentamidine to avoid hypocalcemia.

Keep away from light and store in a sealed container.

100ml:2.4g

24 months

Hainan Zhuotai Pharmaceutical Co., Ltd.

• Founded in:

  2016-07-01

• Address:

  No. 2, Yaogu 2nd Road, Yaogu Industrial Park, National Technology and Industrial Development Zone, Haikou City, Hainan Province

• Tax NO.:

  91460100MA5RD0M01X

• Registered Funds:

  95.8 million yuan

• Website:

  Log in to view

• Email:

  Log in to view